SG11201808479VA - Live, attenuated alphavirus constructs and methods and uses thereof - Google Patents
Live, attenuated alphavirus constructs and methods and uses thereofInfo
- Publication number
- SG11201808479VA SG11201808479VA SG11201808479VA SG11201808479VA SG11201808479VA SG 11201808479V A SG11201808479V A SG 11201808479VA SG 11201808479V A SG11201808479V A SG 11201808479VA SG 11201808479V A SG11201808479V A SG 11201808479VA SG 11201808479V A SG11201808479V A SG 11201808479VA
- Authority
- SG
- Singapore
- Prior art keywords
- live
- international
- methods
- attenuated
- constructs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36161—Methods of inactivation or attenuation
- C12N2770/36162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 1111111110111111 11111 01011111011101011101111111111111110111111111110111111 International Bureau Yejd :::„, (10) International Publication Number (43) International Publication Date WO 2017/172698 Al 5 October 2017 (05.10.2017) IN I PO I P CT (51) (21) (22) (25) Filing Language: (26) Publication Language: (30) (71) (72) (74) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 39/12 (2006.01) Cl 2N 15/86 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 7/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2017/024450 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 28 March 2017 (28.03.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Priority Data: 62/316,264 31 March 2016 (31.03.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, Applicant: TAKEDA VACCINES, INC. [US/US]; One GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Takeda Parkway, Deerfield, IL 60015 (US). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Inventors: LIVENGOOD, Jill, Ann; 2348 Hampshire DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Court, Fort Collins, CO 80526 (US). POWELL, Timothy, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Duane; 5 Blue Jay Way, Maynard, MA 01754 (US). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Agents: HANSON, Roberta et al.; 2200 Wells Fargo Cen- GW, KM, ML, MR, NE, SN, TD, TG). ter, 90 South Seventh St., Minneapolis, MN 55402-3901 Published: (US). — with international search report (Art. 21(3)) [Continued on next page] = . = LIVE, ATTENUATED ALPHAVIRUS CONSTRUCTS AND METHODS AND USES THEREOF (57) : Embodiments herein relate to live, attenuated alphaviruses that are incapable Vero Growth Curve of replicating in mosquito cells and of transmis- sion by mosquito vectors. Other embodiments 1.E+09 -,-*--FMDV concern methods of generating live, attenuated alphaviruses, constructs thereof and uses of Title: (54) = = - _ _ = — 1.E+08 .4%--HC V these live, attenuated alphaviruses in immuno- = genic compositions. Other embodiments relate 1.E+07 -it- E V71 to pharmaceutical compositions including the 1.E+06 live, attenuated alphaviruses and methods for _, = = .4 TME V manufacturing these live, attenuated viruses. -X- E I .E+05 Yet other embodiments relate to uses of these C tn 1.E+04 -- --- - -.)-ii-FIRV compositions in kits for portable applications = such as vaccines against alphavirus infection U1.E+03 -4I-CHIK- and methods thereof. Emi . = — — 1.E+02 IRES --.- . -..181-25 1.E+01 r 1.E+00 mock 1 2 3 Day FIG. 3 1-1 pc 01 N N 1-1 N 1-1 0 ei O WO 2017/172698 Al MIDEDIMOM0101011101010MOINIHOHINIMEMOVOIMIE — before the expiration of the time limit for amending the — with sequence listing part of description (Rule 5.2(a)) claims and amendments (Rule to be republished 48.2(h)) in the event of receipt of
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662316264P | 2016-03-31 | 2016-03-31 | |
PCT/US2017/024450 WO2017172698A1 (en) | 2016-03-31 | 2017-03-28 | Live, attenuated alphavirus constructs and methods and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201808479VA true SG11201808479VA (en) | 2018-10-30 |
Family
ID=58501809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201808479VA SG11201808479VA (en) | 2016-03-31 | 2017-03-28 | Live, attenuated alphavirus constructs and methods and uses thereof |
Country Status (17)
Country | Link |
---|---|
US (1) | US20190106682A1 (en) |
EP (1) | EP3436062A1 (en) |
JP (1) | JP2019509750A (en) |
KR (1) | KR20180135913A (en) |
CN (1) | CN109195625A (en) |
AU (1) | AU2017241669A1 (en) |
BR (1) | BR112018069079A2 (en) |
CA (1) | CA3019536A1 (en) |
CO (1) | CO2018010359A2 (en) |
CR (1) | CR20180457A (en) |
DO (1) | DOP2018000209A (en) |
EC (1) | ECSP18081582A (en) |
MX (1) | MX2018011839A (en) |
PE (1) | PE20190178A1 (en) |
PH (1) | PH12018502120A1 (en) |
SG (1) | SG11201808479VA (en) |
WO (1) | WO2017172698A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020013236A (en) | 2018-06-06 | 2021-02-22 | Massachusetts Inst Technology | Circular rna for translation in eukaryotic cells. |
CN110213711B (en) * | 2019-04-22 | 2021-06-18 | 腾讯科技(深圳)有限公司 | Resident point estimation method, device, equipment and medium |
CN114561366B (en) * | 2022-03-30 | 2023-06-20 | 西南民族大学 | Goat kuraria virus isolate and application thereof |
CN117925540B (en) * | 2024-03-22 | 2024-06-18 | 北京昭衍新药研究中心股份有限公司 | CV2117-HAV-HTLV-2 polygene pseudovirus and preparation method and application thereof |
CN118127077B (en) * | 2024-05-08 | 2024-07-16 | 南京农业大学三亚研究院 | Chimeric alphavirus preparation method and application based on Katavirus skeleton |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050112095A1 (en) * | 2002-07-09 | 2005-05-26 | Tsu-An Hsu | Internal ribosome entry sites for recombinant protein expression |
KR101913790B1 (en) * | 2008-01-24 | 2018-12-28 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Attenuated Recombinant Alphaviruses Incapable of Replicating in Mosquitoes and Uses Thereof |
-
2017
- 2017-03-28 CR CR20180457A patent/CR20180457A/en unknown
- 2017-03-28 WO PCT/US2017/024450 patent/WO2017172698A1/en active Application Filing
- 2017-03-28 AU AU2017241669A patent/AU2017241669A1/en not_active Abandoned
- 2017-03-28 US US16/088,815 patent/US20190106682A1/en not_active Abandoned
- 2017-03-28 BR BR112018069079A patent/BR112018069079A2/en not_active IP Right Cessation
- 2017-03-28 MX MX2018011839A patent/MX2018011839A/en unknown
- 2017-03-28 JP JP2018551252A patent/JP2019509750A/en not_active Withdrawn
- 2017-03-28 CN CN201780032818.3A patent/CN109195625A/en active Pending
- 2017-03-28 EP EP17716083.5A patent/EP3436062A1/en not_active Withdrawn
- 2017-03-28 KR KR1020187031480A patent/KR20180135913A/en not_active Application Discontinuation
- 2017-03-28 PE PE2018001927A patent/PE20190178A1/en unknown
- 2017-03-28 SG SG11201808479VA patent/SG11201808479VA/en unknown
- 2017-03-28 CA CA3019536A patent/CA3019536A1/en not_active Abandoned
-
2018
- 2018-09-27 CO CONC2018/0010359A patent/CO2018010359A2/en unknown
- 2018-09-28 DO DO2018000209A patent/DOP2018000209A/en unknown
- 2018-10-01 PH PH12018502120A patent/PH12018502120A1/en unknown
- 2018-10-30 EC ECSENADI201881582A patent/ECSP18081582A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2017172698A1 (en) | 2017-10-05 |
CA3019536A1 (en) | 2017-10-05 |
PE20190178A1 (en) | 2019-02-01 |
EP3436062A1 (en) | 2019-02-06 |
PH12018502120A1 (en) | 2019-07-15 |
CR20180457A (en) | 2019-04-09 |
MX2018011839A (en) | 2019-05-23 |
US20190106682A1 (en) | 2019-04-11 |
KR20180135913A (en) | 2018-12-21 |
CO2018010359A2 (en) | 2018-12-14 |
BR112018069079A2 (en) | 2019-01-29 |
ECSP18081582A (en) | 2019-02-28 |
AU2017241669A1 (en) | 2018-11-22 |
JP2019509750A (en) | 2019-04-11 |
CN109195625A (en) | 2019-01-11 |
DOP2018000209A (en) | 2019-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201808479VA (en) | Live, attenuated alphavirus constructs and methods and uses thereof | |
SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
SG11201809710RA (en) | Genetically engineered cells and methods of making the same | |
SG11201901550WA (en) | Method and apparatus for data processing | |
SG11201906161VA (en) | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | |
SG11201803983UA (en) | Transformable tagging compositions, methods, and processes incorporating same | |
SG11201908478SA (en) | Sterilisation method | |
SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
SG11201907846VA (en) | Therapeutic rna | |
SG11201807269PA (en) | Filamentous fungal biomats, methods of their production and methods of their use | |
SG11201910096RA (en) | Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201808715RA (en) | Electro-polarizable compound and capacitor | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
SG11201909495PA (en) | Combination cancer immunotherapy with pentaaza macrocyclic ring complex | |
SG11201811831SA (en) | Compositions and methods for stabilizing flaviviruses with improved formulations | |
SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
SG11201901518WA (en) | Methods for producing virus for vaccine production | |
SG11201804888WA (en) | Velocity model update with an inversion gradient | |
SG11201900123TA (en) | Compositions and methods for treating frontotemporal dementia | |
SG11201809993VA (en) | Oncolytic viruses comprising esrage and methods of treating cancer | |
SG11201902988UA (en) | Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof |